Augurex Partners with ARUP Laboratories to Launch 14-3-3η Test for Rheumatoid Arthritis

Augurex Life Sciences Corp., a leader in autoimmune biomarker diagnostics, has announced that ARUP Laboratories, a prominent national reference lab in the U.S., has launched the 14-3-3η test as part of its diagnostic offerings. This agreement is set to significantly…

Read MoreAugurex Partners with ARUP Laboratories to Launch 14-3-3η Test for Rheumatoid Arthritis
Bayer

BeiGene Gets CHMP Nod for TEVIMBRA® in Advanced Gastric and Esophageal Cancers

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued positive opinions recommending an extended authorization for TEVIMBRA® (tislelizumab)…

Read MoreBeiGene Gets CHMP Nod for TEVIMBRA® in Advanced Gastric and Esophageal Cancers

Bruker Unveils $100 High-Accuracy Plasma Proteome for Glycoproteomics and Metaproteomics

At the 23rd Human Proteome Organization World Congress, Bruker Corporation (Nasdaq: BRKR) announced significant advancements in deep, unbiased, and high-sensitivity 4D-Proteomics. These developments enable robust, high-fidelity, large-scale studies while minimizing the inherent cross-talk issues associated with affinity high-plex technologies. A.…

Read MoreBruker Unveils $100 High-Accuracy Plasma Proteome for Glycoproteomics and Metaproteomics
Pfizer

NUCLIDIUM Begins Phase 1 Study of 61Cu Radiotracer in PSMA-Positive Prostate Cancer

NUCLIDIUM has announced the successful imaging of its first patient in a Phase 1 clinical trial for its radiotracer candidate, aimed at providing a safe and accurate diagnostic tool for prostate cancer. The radiotracer, 61Cu-NuriPro™ (61Cu-NODAGA-PSMA I&T), targets Prostate Specific…

Read MoreNUCLIDIUM Begins Phase 1 Study of 61Cu Radiotracer in PSMA-Positive Prostate Cancer

ASDS 2024: Phase III READY-4 Data Show Long-Term Safety and Efficacy of Galderma’s Relfydess™

Galderma has announced new Phase III data from the READY-4 clinical trial, showcasing the long-term safety and efficacy of RelabotulinumtoxinA (Relfydess™) for treating frown lines and crow’s feet after repeated injections. The study met its primary and secondary endpoints, revealing…

Read MoreASDS 2024: Phase III READY-4 Data Show Long-Term Safety and Efficacy of Galderma’s Relfydess™

Seaport Therapeutics Secures $225 Million in Oversubscribed Series B Funding

Seaport Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative neuropsychiatric medicines, has successfully closed an oversubscribed $225 million Series B financing round. The round was led by General Atlantic, a prominent global growth investor, with participation from T. Rowe…

Read MoreSeaport Therapeutics Secures $225 Million in Oversubscribed Series B Funding

Definitive Healthcare Launches Monocl Conferences for Biopharma and Medtech

Definitive Healthcare (Nasdaq: DH) has launched Monocl Conferences, a new solution aimed at improving conference planning and participation for life science organizations. This platform provides medical affairs, marketing, and conference planning teams with detailed, contextualized data on key conferences, helping…

Read MoreDefinitive Healthcare Launches Monocl Conferences for Biopharma and Medtech